This review highlights CRISPR’s potential to provide durable, scalable, and cost-effective HIV control, particularly in low-resource settings and underscores a hopeful vision that precise gene editing may transform HIV therapy from lifelong suppression into a pathway toward functional cure.
Z. Safaei, K. Khalili· Journal of Neurovirology· 0 citations
It is demonstrated that intact and potentially replication-competent virus persists in the primate brain under ART and that systemic AAV9-CRISPR can reach and edit proviral DNA in this sanctuary, supporting genome editing as a strategy toward durable remission of CNS reservoirs.
Hong Liu, Shu-Ren Liao, Chen Chen et al.· Molecular Therapy: Nucleic A...· 1 citation
HIV has challenged humanity for decades, quietly establishing latent reservoirs that evade even the most potent antiretroviral therapies (ART). While ART transformed HIV from a fatal disease into a manageable condition, the virus’s hidden persistence continues to fuel the global epidemic. This review narrates the story...
Z. Safaei, K. Khalili· Journal of Neurovirology· 0 citations
It is demonstrated in vitro that CRISPR can be used to excise the HTLV-1 genome and reduce proviral loads in PBMCs from HAM/TSP patients and may serve as a platform for curing HAM/TSP.
Samuel Brancazio, K. Khalili, Steven Jacobson et al.· Journal of Neurovirology· 0 citations
The combination knockout of CCR5, MOGS, and viral sequences profoundly reduces HIV-1 replication in an ex vivo cellular model, that is, HIV-1-infected peripheral blood mononuclear human cells, thus offering a pathway to launch further preclinical studies.
Z. Safaei, Anna Bellizzi, Hong Liu et al.· Human Gene Therapy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
